Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 30;4(3):247-259.
doi: 10.3233/BLC-180169.

Antibody-Drug Conjugates in Bladder Cancer

Panagiotis J Vlachostergios  1 , Christopher D Jakubowski  1 , Muhammad J Niaz  1 , Aileen Lee  1 , Charlene Thomas  1 , Amy L Hackett  1 , Priyanka Patel  1 , Naureen Rashid  1 , Scott T Tagawa  1   2   3
Affiliations
Review

Antibody-Drug Conjugates in Bladder Cancer

Panagiotis J Vlachostergios et al. Bladder Cancer. .

Abstract

Urothelial carcinoma (UC) is characterized by expression of a plethora of cell surface antigens, thus offering opportunities for specific therapeutic targeting with use of antibody-drug conjugates (ADCs). ADCs are structured from two major constituents, a monoclonal antibody (mAb) against a specific target and a cytotoxic drug connected via a linker molecule. Several ADCs are developed against different UC surface markers, but the ones at most advanced stages of development include sacituzumab govitecan (IMMU-132), enfortumab vedotin (ASG-22CE/ASG-22ME), ASG-15ME for advanced UC, and oportuzumab monatox (VB4-845) for early UC. Several new targets are identified and utilized for novel or existing ADC testing. The most promising ones include human epidermal growth factor receptor 2 (HER2) and members of the fibroblast growth factor receptor axis (FGF/FGFR). Positive preclinical and early clinical results are reported in many cases, thus the next step involves further improving efficacy and reducing toxicity as well as testing combination strategies with approved agents.

Keywords: Antibody-drug conjugate; bladder cancer; targeted therapy; urothelial carcinoma.

PubMed Disclaimer

Figures

Fig.1
Fig.1
111In-J591 single-photon-emission tomography (SPECT) in a patient with metastatic bladder urothelial carcinoma (UC). From left to right: coronal, sagittal and transaxial views from SPECT/CT obtained 72 hours after the administration of 5.55 mCi In-111 DOTA J-591. (A) CT images of the head showing a focal hyperintense lesion with surrounding edema in the right hemisphere. (B) SPECT images of the head in grayscale and (C) in color scale, showing multiple foci of increased uptake in the brain, skull, mandibles and cervical nodes.
See this image and copyright information in PMC

References

    1. Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–75. - PubMed
    1. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol. 2015;68(5):868–79. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
    1. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol. 1992;10(7):1066–73. - PubMed
    1. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8. - PubMed